Barchart.com
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Editas Medicine (EDIT)

Editas Medicine (EDIT)
1.5600 unch (unch) 14:05 ET [NASDAQ]
1.5600 x 732 1.5700 x 791
Realtime by (Cboe BZX)
1.5600 x 732 1.5700 x 791
Realtime 1.5600 unch (unch) 09:30 ET
News & Headlines for Thu, Apr 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Editas Medicine Announces Chief Financial Officer Transition GlobeNewswire - Thu Mar 20, 3:01PM CDT

EDIT : 1.5600 (unch)
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential Stocktwits - Wed Mar 5, 9:16PM CST

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

IBB : 122.99 (+0.81%)
EDIT : 1.5600 (unch)
VTI : 268.40 (+1.88%)
IWM : 193.77 (+1.85%)
Editas: Q4 Earnings Snapshot AP - Wed Mar 5, 3:32PM CST

Editas: Q4 Earnings Snapshot

EDIT : 1.5600 (unch)
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates GlobeNewswire - Wed Mar 5, 3:05PM CST

EDIT : 1.5600 (unch)
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March GlobeNewswire - Mon Feb 24, 8:00AM CST

EDIT : 1.5600 (unch)
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities GlobeNewswire - Mon Jan 13, 8:00AM CST

EDIT : 1.5600 (unch)
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Jan 6, 8:00AM CST

EDIT : 1.5600 (unch)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce Zacks Investment Research - Mon Dec 16, 2024

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 0.7511 (+2.86%)
CSTL : 20.99 (-1.32%)
EDIT : 1.5600 (unch)
SPRO : 0.7250 (-0.29%)
Editas Medicine Advances In Vivo CRISPR-Edited Medicines, Announces Workforce Reduction and Strategic Transition Quiver Quantitative, Inc. - Fri Dec 13, 2024

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases.Quiver AI SummaryEditas Medicine, Inc. has announced...

EDIT : 1.5600 (unch)
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years GlobeNewswire - Thu Dec 12, 2024

EDIT : 1.5600 (unch)

Barchart Exclusives

This Under-the-Radar Energy Stock Is Heating Up Barchart - 4 minutes ago
Atmos Energy Corporation (ATO) is a regulated natural gas distributor with a strong focus on modernizing its network and reducing regulatory lag. ATO has a 100% technical “buy” signal and is trading above all its daily moving averages. Wall Street analysts and major investing advisory services are bullish, with multiple... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot